On May 25th Empros Pharma started our second clinical trial – a Phase IIa proof-of-concept trial. It is a golden standard randomized, placebo controlled double blinded clinical trial where we compare two different doses of EMP16-02 and placebo. The primary endpoint is placebo adjusted weight loss after 26 weeks of treatment with EMP16-02.
In only three months the recruitment was complete with 156 patients included in three study arms. We have had a fantastic interest from patients to participate in the trial; more than 2.000 patients applied. Our CRO succeeded very well in recruitment.
We expect top-line data during Q2 2021.